Angiogenesis: Novel Basic Science Insights and Human Therapy Organizer(s): Napoleone Ferrara, Shahin Rafii and Elisabetta Dejana Date: January 13 - 18, 2004
Location: Eldorado Hotel & Spa, Santa Fe, NM, USAThe establishment of a blood supply has been long known to be of fundamental importance for embryonic development, reproductive functions, tumorigenesis and many other proliferative processes. Over the last decade, major progress has been made in the identification of some key angiogenic inducers and several anti-angiogenic molecules. Substantial advances have been also made in the understanding of the regulation of angiogenesis by oxygen tension and other mechanisms. However, many important questions are still unanswered. For example, the traditional concept that angiogenesis occurs by sprouting of resident endothelial cells has been complemented by the finding that bone marrow-derived progenitor cells can be incorporated in the vessels, but the contribution of these elements in various pathophysiologic situations remains to be determined. Also, the identification of at least one tissue-specific angiogenic factor suggests a greater level of complexity and specialization than previously appreciated. An issue intensely debated in the field is the interplay and cooperation among soluble factors and extracellular matrix proteins to achieve not only morphogenesis but also diversity among blood vessels in different organs. In addition, clinical testing of angiogenesis inducers and inhibitors is in advanced stage and results of some pivotal trials will be known by the time the meeting takes place. The objective of this meeting is to discuss the latest basic science findings and review the status of the clinical application of angiogenic growth factors and inhibitors; learn the latest molecular and genetic findings on the regulation of angiogenesis; acquire an integrated view of the role of blood vessels in health and disease; discuss the results of then initial pivotal clinical trials in angiogenesis and anti-angiogenesis; and identify the pathological conditions that are most likely to benefit from such treatments. Discounted Abstract Deadline: September 22 2003 Discounted Registration Deadline: November 13 2003 We gratefully acknowledge additional support for this conference from: Abbott Laboratories    |